TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23410871
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg for 4 weeks and atorvastatin 20 mg for 20 weeks without pre-PCI loading dose (Group B)
Study: 23410871
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg for 24 weeks only post-PCI (Group C)
Study: 21639907
Drug: Infliximab alone
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab alone (5 mg/kg at weeks 0, 2, 6, 12, and 18)
Study: 21639907
Drug: Infliximab combined
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab combined with Methotrexate (10 mg/week)
Study: 3429863
Drug: Nicardipine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 50 mg twice daily for 3 weeks
Study: 8085125
Drug: 50% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% glucose solution
Study: 27927030
Drug: Balance specific
Normalized name: Rebalance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balance specific rehabilitation, 20 treatment sessions
Study: 27927030
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treatments to reduce limitations at activity and body function level, 20 treatment sessions
Study: 25873634
Drug: ETN 50
Normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETN 50 mg QW + MTX
Study: 25873634
Drug: ETN 25
Normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETN 25 mg QW + MTX
Study: 22752489
Drug: Donepezil (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (2.5 mg daily for initial 4 weeks followed by 5 mg daily for next 8 weeks)
Study: 8673350
Drug: Psychopharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychopharmacological treatment (alprazolam + sulpiride)
Study: 8673350
Drug: Psychopharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychopharmacological treatment (alprazolam + sulpiride) plus social support by volunteers (SSV)
Study: 8673350
Drug: Psychopharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychopharmacological treatment (alprazolam + sulpiride) plus structured psychotherapy (autogenous training)
Study: 28847527
Drug: Intravenous ascorbic
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ascorbic acid (IVAA) administered simultaneously with modulated electrohyperthermia (mEHT)
Study: 28847527
Drug: Intravenous ascorbic
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ascorbic acid (IVAA) administered after modulated electrohyperthermia (mEHT)
Study: 28847527
Drug: Intravenous ascorbic
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ascorbic acid (IVAA) administered before modulated electrohyperthermia (mEHT)
Study: 28847527
Drug: Solely intravenous
Normalized name: English sole
DrugBank: English sole (DB10904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solely intravenous ascorbic acid (IVAA)
Study: 26363163
Drug: Olfactory training
Normalized name: BOS TAURUS OLFACTORY BULB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olfactory training (TR group) - twice daily exposure to 4 odours (rose, eucalyptus, lemon, clove) for approximately 12 weeks
Study: 21176784
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg modafinil + placebo
Study: 21176784
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg THC + placebo
Study: 21176784
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg modafinil + 15 mg THC
Study: 15545308
Drug: M100240 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: M100240 50 mg with a high-fat meal
Study: 15545308
Drug: M100240 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: M100240 50 mg under fasted conditions
Study: 12399343
Drug: Ongoing intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ongoing intervention (active treatment with care management by practice nurses over 24 months)
Study: 1972648
Drug: Cetirizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (10 mg twice a day for 4 days)
Study: 15561050
Drug: Closed perfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed perfusion system with heparin coating and centrifugal pump
Study: 11376665
Drug: Nitroglycerin in
Normalized name: nitroglycerin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin in the form of transdermal therapeutic system releasing 5 mg of nitroglycerin in 24 h
Study: 9259112
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg acetylsalicylic acid (ASA) per day
Study: 3125269
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg diflunisal 2 h preoperatively and then 500 mg twice daily for 2.5 days
Study: 3125269
Drug: Veralgin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veralgin (1 tablet twice daily beginning 2 h prior to operation)
Study: 27184779
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered every other day for 2 weeks)
Study: 22851734
Drug: Dark chocolate
Normalized name: Ensure Original Dark Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dark chocolate (100 g/d for 3 days)
Study: 19034538
Drug: 1% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% chlorhexidine gel (Corsodyl) applied for 30 seconds
Study: 17687578
Drug: Interactive visuo-motor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive visuo-motor therapy system (VR-based motor neurorehabilitation)
Study: 8044962
Drug: Enoxaparin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (40 mg/d SC for 1 month)
Study: 2854455
Drug: Fluconazole 50
Normalized name: fluconazole 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 50 mg per day orally for 14 days
Study: 28737409
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg immediate-release tablet of ibuprofen
Study: 20626531
Drug: Itraconazole pulse
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole pulse regimen (200 mg b.i.d. for 1 week, off for 3 weeks)
Study: 20626531
Drug: Continuous regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous regimen (Itraconazole 100 mg b.i.d. continuously)
Study: 17710021
Drug: High-dose I-131
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose I-131 therapy
Study: 11778950
Drug: Vitamin B1
Normalized name: Vitamin B1
DrugBank: Monophosphothiamine (DB16023)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B1 (75 mg, once a day) for 1 month
Study: 11778950
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (250 mg, twice a day) for 1 month
Study: 9472838
Drug: Venlafaxine 150
Normalized name: venlafaxine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 150 mg/day
Study: 9472838
Drug: Venlafaxine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 200 mg/day
Study: 2565119
Drug: Control (Drug-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Drug-free period)
Study: 27826345
Drug: Conventional Treatment
Normalized name: PECTIN 11.5 mg in 7 g ORAL LOZENGE [Lolleez Birthday Cake - Conventional]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Treatment
Study: 25733201
Drug: Pioglitazone (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (45 mg per day) plus Metformin (1000 mg twice per day)
Study: 25733201
Drug: Pioglitazone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone plus Metformin
Study: 23392759
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg two or three times a day
Study: 20306771
Drug: Self-reported health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported health complaints and use of medicines among females
Study: 16904773
Drug: Intravenous sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sedation (Fentanyl and Midazolam)
Study: 10897096
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of racemic chlorpheniramine (8 mg)
Study: 10897096
Drug: Vietnamese-tested formulation
Normalized name: Vietnamese centipede preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vietnamese-tested formulation of racemic chlorpheniramine (8 mg)
Study: 1813860
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g vitamin C daily
Study: 6095659
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg at bedtime)
Study: 21271232
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion (1 µg/kg BW/h for 10 min, then 0.2-0.4 µg/kg BW/h)
Study: 16979847
Drug: Disulfiram 62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram 62.5 mg/day with cocaine 0.25 mg/kg
Study: 16979847
Drug: Disulfiram 250
Normalized name: disulfiram 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram 250 mg/day with cocaine 0.25 mg/kg
Study: 16979847
Drug: Disulfiram 62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram 62.5 mg/day with cocaine 0.5 mg/kg
Study: 16979847
Drug: Disulfiram 250
Normalized name: disulfiram 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram 250 mg/day with cocaine 0.5 mg/kg
Study: 16979847
Drug: Cocaine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine 0.25 mg/kg
Study: 15482040
Drug: Manual-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual-based cognitive-behavioral treatment for anxiety
Study: 15482040
Drug: Increased involvement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased involvement during therapy (positive involvement shifts)
Study: 10342793
Drug: 1.25 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg/day bendrofluazide
Study: 2812168
Drug: Daily machine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily machine haemofiltration (MHF)
Study: 1251146
Drug: Sustained-release KC1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release KC1 preparation
Study: 1251146
Drug: Non-sustained-release KC1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-sustained-release KC1 coated tablet
Study: 30739130
Drug: Toreforant 30
Normalized name: Toreforant
DrugBank: Toreforant (DB12522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toreforant 30 mg/day (weeks 0-52)
Study: 30739130
Drug: Placebo (weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (weeks 0-12) followed by toreforant 30 mg/day (weeks 12-52)
Study: 24359521
Drug: Baoji Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baoji Tablets 0.9 g and dummy Baoji Pills 3.7 g
Study: 24359521
Drug: Dummy Baoji
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dummy Baoji Tablets 0.9 g and Baoji Pills 3.7 g
Study: 24359521
Drug: Dummy Baoji
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dummy Baoji Tablets 0.9 g and dummy Baoji Pills 3.7 g
Study: 16878346
Drug: Levetiracetam 1000
Normalized name: levetiracetam 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam 1000 mg immediate release (IR) formulation
Study: 10885587
Drug: Ibuprofen 7
Normalized name: hydrocodone-ibuprofen 7.5 mg-200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 7 mg/kg in suspension
Study: 10885587
Drug: Ibuprofen 200
Normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 200 or 400mg as effervescent granules
Study: 9058443
Drug: Inulin (30-35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inulin (30-35 g/d) for 1 week
Study: 28288613
Drug: Anti-gravity treadmill
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-gravity treadmill (alter G®) treatment, 20 min sessions, 2-3 times per week for 6 weeks
Study: 18555997
Drug: Quadrivalent HPV
Normalized name: HPV, quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent HPV 6/11/16/18 vaccine
Study: 12556649
Drug: Amlodipine (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (after dosage adjustment)
Study: 12556649
Drug: Losartan/HCTZ (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan/HCTZ (after dosage adjustment)
Study: 9305484
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral rehydration solution (20 g/L glucose, 94 mmol/L sodium, 292 mOsm/kg osmolality)
Study: 9305484
Drug: Polymeric glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymeric glucose isotonic solution enriched with glutamine (18 g/L Glucidex 12, 14.6 g/L glutamine, 94 mmol/L sodium, 282 mOsm/kg osmolality)
Study: 8409300
Drug: cisapride 20
Normalized name: cisapride 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cisapride 20 mg b.i.d.
Study: 2866133
Drug: ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ranitidine 150 mg b.i.d.
Study: 8409300
Drug: cisapride 20
Normalized name: cisapride 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cisapride 20 mg b.i.d. + ranitidine 150 mg b.i.d.
Study: 3891488
Drug: Captopril long-term
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril long-term treatment (75 or 150 mg daily)
Study: 31069579
Drug: HIPEC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIPEC treatment
Study: 25182247
Drug: Rivaroxaban (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (20 mg once daily, 15 mg if creatinine clearance was between 30 and 49 mL/min)
Study: 1659437
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg twice daily) plus sumatriptan (300 mg orally)
Study: 1659437
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus sumatriptan (300 mg orally)
Study: 25793773
Drug: 3 day
Normalized name: Kathro 3 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 day regimen (2 injections of 7 mg/kg in 3 days)
Study: 25793773
Drug: 7 day
Normalized name: ZonaCort 7 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 day regimen (3 injections of 4 mg/kg per injection in 7 days)
Study: 14671247
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (perindopril and indapamide for eligible participants)
Study: 7679610
Drug: Bleomycin administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleomycin administered intravenously on a weekly basis
Study: 7679610
Drug: Oral etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral etoposide therapy
Study: 7679610
Drug: Radiation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation treatment regimens (8 Gy in a single fraction and 20 Gy in ten fractions)
Study: 3689634
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg day‐1) for 9 days
Study: 28940192
Drug: Oral language
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral language programme (N = 103)
Study: 26829343
Drug: Pelvic Floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic Floor Physical Therapy (PFPT) - 4 sessions
Study: 25060372
Drug: Post-operative antibiotic
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative antibiotic duration >48 h
Study: 19757213
Drug: Berberine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berberine (300 mg orally three times daily)
Study: 10381042
Drug: MTX 15-20
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX 15-20 mg/week
Study: 6131683
Drug: Suxamethonium 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxamethonium 1 mg kg‐1 followed by Org NC 45 40 micrograms kg‐1 5 min after recovery (group I)
Study: 6131683
Drug: Suxamethonium 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxamethonium 1 mg kg‐1 followed by Org NC 45 40 micrograms kg‐1 15 min after recovery (group II)
Study: 6131683
Drug: Suxamethonium 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxamethonium 1 mg kg‐1 followed by Org NC 45 40 micrograms kg‐1 30 min after recovery (group III)
Study: 6131683
Drug: Suxamethonium 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxamethonium 1 mg kg‐1 followed by Org NC 45 (groups I, II, III)
Study: 21428467
Drug: Histamine dihydrochloride
Normalized name: Histamine dihydrochloride
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Histamine dihydrochloride and IL-2 as maintenance therapy
Study: 21428467
Drug: Histamine dihydrochloride
Normalized name: Histamine dihydrochloride
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Histamine dihydrochloride and IL-2 therapy
Study: 16884465
Drug: Caudal group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal group (1 ml.kg(‐1) 0.25% bupivacaine)
Study: 10615738
Drug: Naltrexone only
Normalized name: Naltrexone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone only (50 mg once daily)
Study: 10615738
Drug: Naltrexone with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone with nicotine patches (50 mg once daily + 21 mg/24-hour for first 8 weeks, 14 mg/24-hour for last 4 weeks)
Study: 10615738
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with nicotine patches
Study: 1523998
Drug: Pirarubicin (THP)
Normalized name: pirarubicin
DrugBank: Pirarubicin (DB11616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirarubicin (THP) instillation at a dose of 500 micrograms/ml, 3 times per week for 3 weeks
Study: 1523998
Drug: Adriamycin (ADM)
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin (ADM) instillation at a dose of 500 micrograms/ml, 3 times per week for 3 weeks
Study: 6497936
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg tamoxifen daily for 2 months
Study: 30963353
Drug: Insulin-loaded liposomal
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-loaded liposomal chitosan gel
Study: 27036515
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (traditional therapy)
Study: 18083469
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 mcg/kg IV for 10 minutes followed by 0.3 mcg/kg IV for 50 minutes)
Study: 18083469
Drug: Propacetamol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propacetamol (2 g IV for 10 minutes)
Study: 16026220
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) with adjunctive parent component
Study: 16026220
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) without parent component
Study: 11925385
Drug: Dexamethasone (DXM)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DXM) treatment in patients with elevated progesterone levels
Study: 11925385
Drug: ACTH administration
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH administration during suppression of endogenous gonadotrophin secretion
Study: 8691565
Drug: G-CSF (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (200 micrograms/m2 iv) administration starting 24 hrs after chemotherapy (Group A)
Study: 8691565
Drug: G-CSF (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (200 micrograms/m2 iv) administration after a febrile episode of 38 degrees C with neutropenia (Group B)
Study: 8691565
Drug: G-CSF (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (Group A)
Study: 420326
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment control periods
Study: 2107608
Drug: Standard PN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard PN solution
Study: 109382
Drug: Butalamine hydrochloride
Normalized name: butalamine hydrochloride
DrugBank: Butalamine (DB13681)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butalamine hydrochloride tablets (80 mg each), daily dose of 3 x 2 tablets
Study: 109382
Drug: Butalamine hydrochloride
Normalized name: butalamine hydrochloride
DrugBank: Butalamine (DB13681)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butalamine hydrochloride tablets (80 mg each), daily dose of 3 x 1 tablet
Study: 26181221
Drug: Protocolized sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocolized sedation plus daily interruption
Study: 21951313
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab injection (IVBI)
Study: 21951313
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab injection (IVRI)
Study: 21903553
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy without chlorhexidine
Study: 14534519
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (2 mg estradiol valerate and 250 microg levonorgestrel)
Study: 14534519
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (30 microg ethinyl estradiol and 150 microg desogestrel)
Study: 14534519
Drug: Control phase
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control phase (150 mg bupropion without pretreatment)
Study: 7784119
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (discontinuing antibiotic prophylaxis)